Skin Carcinoma Clinical Trial
Official title:
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and Their Primary Care Providers (TEACH)
Verified date | May 2024 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies the impact of a 12-month invention focused on early detection of skin cancer and timely follow up in patients who underwent stem cell transplant and their primary care providers. Some stem cell transplant survivors may develop complications related to the treatment they received. Many of these complications may not be known for years after the treatment and preventive measures can be taken to reduce the chances that a complication will occur and encourage early detection. This study focuses on one complication that stem cell transplant survivors are at high risk of developing - skin cancer. An early diagnosis of skin cancer is important since the cancer is usually smaller, requires less extensive treatments, and has better outcomes. Teaching skin self-examination and encouraging patients to alert doctors to skin changes may provide an important opportunity for early detection of skin cancer.
Status | Active, not recruiting |
Enrollment | 840 |
Est. completion date | March 31, 2025 |
Est. primary completion date | October 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Have undergone autologous or allogeneic hematopoietic stem cell transplantation (HCT) at City of Hope (COH) - Are 2 years (yrs) to 5 yrs (+/- 3 months [m]) after HCT - Have seen a primary care provider (PCP) in the previous 12 m (expected > 95% of all eligible) or planning to do so in next 12 m - Have a mobile phone with the ability to receive text messages - Can fluently read and write in English or Spanish - Can understand and sign the study-specific Informed Consent Form (ICF) Exclusion Criteria: - Patients who have evidence of active hematologic malignancy or acute illness that would limit study participation |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Impact of patient activation and education alone or with physician activation on change in skin cancer screening and health promotion practices | Will administer questionnaires at baseline and 12 months to ask about skin examinations performed within the past 12 months. Will use logistic regression to adjust for imbalance in patient characteristics and risk factors. Will also test for group by covariate interactions, depending on group main effect. | Baseline and 12 months | |
Primary | Time interval between a participant's first notice of a suspect mole or lesion and the date on which a definitive diagnosis was made | Will be a continuous variable, and will employ a generalized linear model to compare the interval between the two study arms, adjusted for covariates of interest. Will begin with bivariate models to determine potential variables to include in a multivariable regression model. If the group main effect is significant, interactions of the group main effect with other variables will be examined. | Up to 12 months | |
Primary | Impact of an e-learning teledermoscopy program compared with provision of print materials for identifying suspect lesions | Will compare the group difference in changes in attitude over time, using generalized estimating equation (GEE) for normally distributed data, with a compound symmetry covariance matrix analysis to account for within-physician correlation. Will dichotomize the Likert scale (1-5) response and compare the proportion of primary care physicians (PCPs) reporting a higher (>= 4 versus < 4) level of confidence at 12 months (m) compared to baseline between groups, using the longitudinal binomial GEE model with a compound symmetry covariance structure. Covariate adjustment will be made in these models as necessary. | Up to 12 months | |
Primary | Economic impact on patients - cost-effectiveness analysis | Evaluated using standard incremental cost-effectiveness analysis methods will be used to assess the impact of assumptions and uncertainty on results and conclusions. | Up to 12 months | |
Primary | Economic impact on patients - sensitivity analysis | Evaluated using standard incremental sensitivity analysis will be used to assess the impact of assumptions and uncertainty on results and conclusions. | Up to 12 months | |
Primary | Downstream costs | Will estimate the cost per additional self skin exam completed and the cost per additional PCP exam completed, comparing the two intervention arms. | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01242618 -
Tissue Engineered Nasal Cartilage for Reconstruction of the Alar Lobule
|
Phase 1 | |
Not yet recruiting |
NCT06167096 -
Effects of Lavender Aromatherapy on Patient Anxiety During Mohs Micrographic Surgery
|
N/A | |
Recruiting |
NCT03699995 -
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
|
N/A | |
Completed |
NCT04456140 -
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
|
Phase 1 | |
Terminated |
NCT03630601 -
Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers
|
N/A | |
Recruiting |
NCT03543969 -
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
|
Early Phase 1 | |
Completed |
NCT00783965 -
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
|
Phase 2 | |
Recruiting |
NCT04475640 -
Cancer Genetic Testing in Ethnic Populations
|
N/A | |
Active, not recruiting |
NCT02465060 -
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
|
Phase 2 | |
Completed |
NCT03177057 -
SMART Project in Preventing Skin Cancer
|
N/A | |
Completed |
NCT02417948 -
Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans
|
N/A | |
Completed |
NCT03290989 -
Itch and Pain Characteristics in Skin Carcinomas
|
N/A |